Breaking News

Akorn Completes VersaPharm Acquisition

August 12, 2014

Expands presence in dermatology market

Akorn, Inc. has completed its acquisition of VPI Holdings Corp., the parent company of VersaPharm Inc., for $440 million, expanding its presence in the dermatology market. The transaction is expected to add $90 to $100 million in annual revenues. 
 
"We are excited to announce that we have completed the acquisition of VersaPharm," said Raj Rai, chief executive officer of Akorn. "This highly strategic acquisition further strengthens our niche portfolio and accelerates our long-term growth opportunities."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent